Mechanism-Based Inactivation of CYP2C19 by Anwuligan Resulting in Changes in Pharmacokinetic Properties of Amitriptyline
(39%) and AUC (29-34%). These results demonstrate CYP2C19 inhibition by ANL and its potential to cause clinically relevant drug-drug interactions.
Authors
- Zihao Cheng
- Jiang Zheng (ORCID: https://orcid.org/0000-0002-8187-2147)
- Weiwei Li (ORCID: https://orcid.org/0000-0001-7921-3727)
- Dandan Yang
- X. A. Cheng
- Jie Dai
- Qing Zhang
- Hong Tang
Institutions
- Shenyang Pharmaceutical University (CN)
- Guiyang Medical University (CN)
Publication Details
- Journal
- Chemical Research in Toxicology
- Published
- 2026-04-12
- DOI
- https://doi.org/10.1021/acs.chemrestox.5c00392
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00